Decreased conjugation is probably more important than hemolysis for causing jaundice in G6PD-deficient neonates. The role of enzyme inducers, like phenobarbital, in G6PD deficiency is unclear. This randomized controlled trial was performed to evaluate Phenobarbital's role in reducing the need for phototherapy among G6PD-deficient neonates.
INTRODUCTION
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is a common cause of severe neonatal jaundice, which can be complicated by kernicterus. G6PD deficiency afflicts 6 to 8% of the general population in North-western India. 1 In total, 30 to 40% of G6PD-deficient neonates develop significant jaundice requiring phototherapy or exchange transfusion. 2 Traditionally, hemolysis has been implicated in the pathogenesis of hyperbilirubinemia in G6PD-deficient neonates, but recent evidence suggests that impaired bilirubin conjugation plays a dominant role. This is supported by the fact that in jaundiced G6PD-deficient neonates there are lower levels of bilirubin diglucuronide, 3 normal packed cell volumes (PCV), 4 normal reticulocyte counts 5 and insignificant rise of carboxyhemoglobin. 6 Phenobarbital is an inducer of the enzyme UDP glucuronyl transferase, and appears to be a logical choice for prophylaxis. It also has the advantage of being cheap, easily available and simple to administer. A couple of small, nonrandomized, unblinded trials evaluated prophylactic oral phenobarbital in preventing severe hyperbilirubinemia in G6PD-deficient neonates. 7, 8 These studies carried out in the early 1980s suggested a role of Phenobarbital in preventing jaundice in G6PD deficient neonates. However, due to the methodological weaknesses of these trials, the use of prophylactic phenobarbital did not gain acceptance.
In view of the recent evidence regarding the pathogenesis of hyperbilirubinemia in G6PD deficiency, it was important to have a relook at phenobarbital. Hence, we conducted a randomized, controlled trial to evaluate the role of prophylactic oral phenobarbital in reducing the requirement for phototherapy in G6PD-deficient neonates.
METHODS
This study was conducted in a level III Neonatal Unit of a tertiary care referral hospital in North-west India. It was approved by the institutional Ethics Committee. Written, informed consent was obtained from the parents prior to screening for G6PD deficiency and enrollment.
Subjects
All consecutive babies with gestational age Z34 weeks and weight Z1800 g at birth were screened for G6PD deficiency from the cord blood by fluorescent spot test (FST) performed on a blood sample blotted on a Whatman filter paper. Female babies found normal by FST were further evaluated by methemoglobin elution test for identifying heterozygote status. 9 ''Healthy'' neonates diagnosed to be G6PD-deficient were enrolled into the study within 24 hours of birth, if they fulfilled the eligibility criteria. ''Healthy'' neonates were defined as newborns that were on exclusively oral milk feeds and consistently had normal vital parameters (heart rate, respiratory rate, saturation, blood pressure, temperature) at the time of enrollment into the study. Babies with major congenital malformations, history of maternal use of phenobarbital in the last month of pregnancy, Rh isoimmunization and whose parents refused to give consent, were excluded. The following base line information was recorded: (1) maternal data F history of diabetes, ABO group, TORCH status, induction of labor with oxytocin, family history of hemolytic anemia; (2) intrapartum data F mode of delivery, APGAR score, cord pH; and (3) neonatal data F best estimate of gestational age as assessed by New Ballard's score and the last menstrual period of the mother, birth weight, sex, cord TSB and PCV.
Randomization
Eligible babies were randomized to receive either oral phenobarbital or placebo. Stratified block randomization was done. Stratification was done for two potential confounders, namely, sex and gestational age (34 to 36 and Z37 weeks), to ensure their equal distribution. Each stratum consisted of permuted blocks, of randomly varying sizes.
Administration of Phenobarbital or Placebo
Phenobarbital, available as 30 mg Gardenal s tablets (Biodeal laboratories Pvt Ltd, Wadhwan, Gujarat, India) and the placebo, that is, calcium carbonate, available as 625 mg Shelcal s tablets (Ehler Pharmaceuticals Limited, Navi Mumbai, India) were reconstituted by the pharmacy into identical looking sachets of powdered study drug. The dose was 5 mg/kg/day on the first 3 days of life, with the first dose being administered within the first day of life. In the studies that evaluated the dose effects of phenobarbital on enzyme induction, doses from 3.5 to 10 mg/kg were found to be effective in inducing UDP glucuronyl transferase. 10 The sachets were packed into sets of drug or placebo. There were a sufficient number of sachets to cater for higher birth weights, and for any unexpected wastage. Each set of sachets was allocated a computer-generated random code number, which was decoded after statistical analysis. Each set was placed in a tamper-proof opaque envelope, sealed and labeled with the stratum and serial number. The sealed envelope was opened after the patient identification details were recorded on the outside. The powder was mixed in 10 ml of expressed breast milk or formula milk and then administered to the baby.
Blinding
The subjects (parents), the investigating personnel (nurses administering the drug, resident physicians estimating daily serum bilirubin levels, the chief investigator) and the statistician were blinded to the drug allocation until the end of the analysis. The success of blinding was pretested in a pilot study, where it was found that the nurses could not differentiate powdered phenobarbital from placebo based on their gross appearance or suspension characteristics in breast milk or formula milk.
Outcome Variables and Sample Size
The primary outcome variable was the need for phototherapy and the secondary outcome variables were the duration of phototherapy, need for exchange transfusion, mean peak bilirubin levels, incidence of adverse effects of phenobarbital such as feed intolerance, lethargy and apnea. With an a error of 5% and a power of 80%, a sample size of 56 was required to observe a reduction in the need for phototherapy from 40 to 5%. We chose 40% as the expected need for phototherapy in the control group based on published information, 2 and 5% as the desired rate of phototherapy, because the phototherapy rate in the general population of inborn neonates in our country is about 5%.
11
Monitoring Total serum bilirubin (TSB) and PCV were analyzed every morning until declining TSB values were documented on 2 consecutive days. TSB was estimated by reflectance spectro-photometry using Twin Beam Microbilimeter (Ginevri Technologie Biomediche). In a pilot study, the coefficient of variation of the instrument was found to be less than 5% for TSB levels of 20.9, 10.5 and 5.25 mg%. The instrument was calibrated once every 15 days. The resident physicians were oriented every month on the use of bilirubinometer and its standardization. All jaundiced babies were managed according to the Cockingtons nomograms. 12 Weight, feeding, stooling pattern and urine output were recorded daily.
Statistical Analysis
Categorical variables were compared using Fisher's exact test or w 2 -test, with Yates correction (as required); while numerical variables were analyzed using Student's 't'-test or Mann-Whitney U-test as appropriate. Significance was defined as p<0.05 for all the predefined outcome variables and p<0.01 for other outcome variables explored post hoc.
RESULTS
Overall, 2370 babies were screened for G6PD deficiency and 63 (2. 7%) babies were found deficient. In all, 56 eligible babies were randomly allocated to phenobarbital (n ¼ 27) or placebo (n ¼ 29) groups (Figure 1 ). The mean time of administration of the first, second and third dose of study drug was 18.55±7.3, 33±7 and 51.6±8.8 h of life respectively. No baby regurgitated or vomited any of the doses. Seven eligible babies were excluded before randomization: two for lack of consent, two for being sick, one for maternal phenobarbital, one for malformation and one for Rh isoimmunization.
The sex ratio, mean gestational age, mean birth weight and intrauterine growth status of the babies in the two groups were comparable ( Table 1) . The groups were similar in the maternal use of oxytocin, history of significant jaundice in previous siblings, maternal ABO grouping, cord TSB and PCV. More than 80% babies in both groups were exclusively breastfed and only two babies in each group received intravenous fluids before randomization.
A total of 12 babies (44%) in the phenobarbital group and 12 babies (41%) in the placebo group required phototherapy, and the difference was insignificant (Table 2 ). There was no significant difference in the need for exchange transfusion. The time of need for phototherapy was delayed by a mean of 8.4 hours in the phenobarbital group but this was not statistically significant (p ¼ 0.46). Similarly, in the phenobarbital group, the duration of phototherapy was less by a mean difference of 6 hours, which was not statistically significant.
The mean maximum TSB was similar in both the study and control groups (14.7±6.5 vs 14.25±5.1 mg/dl, respectively; p ¼ 0.79). The two groups were also similar with respect to the time at which the maximum bilirubin was attained, the mean TSB levels on individual days (Figure 2) , the daily rise of bilirubin, the rate of fall of bilirubin from day 3 to day 6 and the PCV on individual days. None of the babies in either group had any episode of apnea or feed intolerance. One baby in each group was lethargic and both these babies were premature.
The action of phenobarbital on hepatic enzyme induction may take some time, hence, we analyzed the influence of the time of starting the course of phenobarbital on its efficacy. We found that in the phenobarbital group, there was no significant difference in the mean time of administration of the first dose between the subjects who needed phototherapy vs the ones who did not (17.5±7.6 h vs 19.9±6.1 hours, respectively; p ¼ 0.19). Patients who received the first dose of phenobarbital within 12 hours of birth required phototherapy as frequently as those who received after 12 hours.
Since the results showed that phenobarbital administration did not make any difference to TSB levels, we combined the two groups and analyzed the entire sample to get an estimate of the time of onset of TSB rise in G6PD deficiency. We found that by the end of the first day, the mean TSB level was 6.9±3 mg/dl and 66% subjects already had a TSB value above 5 mg%. A comparison of the rate of rise of TSB showed that the mean±SD rise of TSB on the first, second, third and fourth days were 5.7±2.9, 3.5±3.2, 2±3.1 and -0.4±4.7 mg/dl respectively. The per day rise of TSB was highest within the first 24 hours of birth (Friedman's test, p< 0.001).
On subgroup analysis, among the subgroups of term, preterm, male and female babies, no difference could be detected in the need for phototherapy, exchange transfusion, mean maximum TSB, hours of onset and duration of phototherapy between those who received phenobarbital or placebo.
DISCUSSION
We selected the ''need for phototherapy'' as the key outcome, because we felt that it was more clinically relevant to be able to reduce the need for a therapy, than merely reduce the incidence of hyperbilirubinemia. We opted to use Cockington's nomograms to decide on the need for phototherapy because these nomograms are action-oriented, giving cutoff values for phototherapy. The AAP guidelines on intervention are not applicable to G6PD-deficient individuals. 13 Cockington's nomograms, though old, are quite compatible with Bhutani's recently published hour-specific total bilirubin data.
14 This validates the intervention values that we used. Since phototherapy always precedes exchange transfusion, the exchange transfusions would not have affected the key outcome of our study. Days of Life Mean serum bilirubin levels (with 95% confidence intervals) from birth to day 7. The rates of rise of bilirubin from birth to 24 hours, from 24 to 48 hours and from 48 to 72 hours and the rate of fall of bilirubin from day 3 to 6 were statistically insignificant.
One possible reason for the lack of clinical effect of phenobarbital in our study could be that mechanisms other than impaired conjugation are important in the pathogenesis of jaundice in G6PD-deficient neonates, and phenobarbital may not act through these mechanisms. At present, these mechanisms are incompletely understood and require further research. Kaplan et al. had proposed that a dose-dependent genetic interaction between the Gilbert syndrome genotype and the G6PD deficiency found among Sephardic Jews could explain the occurrence of jaundice. 15 However, in a study on Sardinian Jews, who have a different genetic background, no such interaction between the UGT1 promoter polymorphism and G6PD could be demonstrated. 16 Beutler 17 had hypothesized that deficiency of the enzyme in the liver may contribute to neonatal jaundice in some individuals, but this has never been proved. The commonest G6PD variant in North-western India is G6PD Mediterranean (563C s T). Less prevalent variants are G6PD Kerala-Kalyan and G6PD Orissa. The interaction of these variants with Gilbert syndrome or hepatic enzyme deficiency remains to be investigated. 18 Another important reason could be that phenobarbital requires some time for inducing the UDP glucuronyl transferase enzyme. It may not get sufficient margin to act before the onset of bilirubin rise in G6PD-deficiency, even if administered early. We were able to administer the drug only at a mean age of 18.55 hours, owing to the turn-around-time for G6PD assay in our laboratory. By the time steady state was reached, 51 hours would have already elapsed, which may have been too late to have effect. Kaplan et al. 19 had shown that TSB levels in G6PD-deficient neonates are higher than normal controls as early as 3 hours of life (2.9±0.7 vs 2.6±0.6 mg/dl, respectively; p<0.05). Kaplan's data and our own data suggest that the rise of TSB in G6PD deficiency occurs very early in life and a slow-acting drug like phenobarbital may not be effective.
In a nonrandomized and unblinded cohort study by Meloni et al. on 66 G6PD-deficient neonates, prophylactic oral phenobarbital on first 5 days was effective in reducing the need for exchange transfusion from 33 to 6%. 7 This study design with its limitations could not eliminate the effects of selection bias and measurement bias. The favorable results in Meloni's study cannot be attributed simply to the higher dose (7 mg/kg day) and duration of Phenobarbital, because work in the early 1980's had clearly showed that phenobarbital in the dose of 5 to 10 mg/kg day for 2 days is as effective as more prolonged treatment. 10 In studies where prophylactic phenobarbital was used for conditions other than G6PD deficiency, the treatment groups had lower mean bilirubin levels than the control, starting from day 3 with the maximum difference being reached on the fifth day or later. 10 The incidence of jaundice and the need for PT or ET were also decreased, particularly in low birth weight infants. In a recent study from North India on 150 babies with birth weight between 1000 to 1500 g, intravenous phenobarbital in the dose of 10 mg/kg given within 6 h of life followed by 5 mg/kg until day 5 of life significantly decreased the need for exchange transfusion (8 vs 32%, p ¼ 0.006) and duration of phototherapy (88±38 vs 125±62 hours, p ¼ 0.06). 20 One of the reasons why phenobarbital may work better in the low birth weight and very low birth weight groups is that, in these settings, the bilirubin rise and peak occurs later than in the G6PD and hemolytic disease settings.
The other drugs that have been tried for prophylaxis in G6PD-deficient neonates are orotic acid 21 and Sn mesoporphyrin. 22 These drugs are expensive, are not available easily and are until in the experimental stages. Valaes et al. in their study on term healthy Greek newborns showed that a single dose of intramuscular Sn mesoporphyrin at 26.7±6.1 hours of age completely eliminated the need for phototherapy among G6PD-deficient neonates. The rise of bilirubin from 24 to 48 hours of age and the peak TSB were significantly lower in newborns that had received Sn mesoporphyrin. 22 In contrast to phenobarbital, this is a very rapidly acting drug that acts by inhibiting the rate-limiting step in bilirubin production.
It is well recognized that jaundice due to G6PD deficiency can occur in heterozygous females. 6,23 -24 Ideally, female heterozygotes should be designated by molecular DNA techniques, rather than by methemoglobin elution. The study design could have been strengthened by measuring serum levels of phenobarbital among the cases; however, this could not be done for logistical reasons.
Ours is the only randomized and blinded study on the role of phenobarbital in G6PD-deficient neonates. On the basis of this study, phenobarbital seems to have no role in prophylaxis of jaundice due to G6PD deficiency. More understanding of the pathogenesis of jaundice in G6PD deficiency is required before studying the potential role of any other drug in preventing hyperbilirubinemia in these neonates.
